It is not a good idea to get "sold" on anything until all the info is in, and at least a few weeks after that. Those cognitive biases are nasty at filtering info you need.
(Saipan Paradise - thanks for posting his stats - newbies don't understand how important it is for getting a meaningful response)
I strongly considered HDRBT monotherapy when I was choosing. Fortunately, I have the best (Demanes) in my backyard. There are a variety of monotherapy protocols that vary the number of insertions, the delay between insertions, the number of fractions, and the dose per fraction. The outcomes don't seem to matter, other than it should never be done in a single fraction.
Experience is important. I remember looking at a report from Moffitt a few years ago, and making a mental note to not recommend to anyone that they go there for it. They have hopefully come along on the learning curve by now.
Frankly, I could have tossed a coin between SBRT and HDRBT. They are radiobiologically identical with respect to doses to the planned target volume and organs at risk. Oncological outcomes and toxicity are nearly the same. There is more data on HDRBT because it was begun in 1995, while SBRT was started in 2003. In the end, I decided for SBRT on the basis of convenience and cost. If possible, I wanted to avoid anesthesia and hospital stays.
Here are some questions to ask at an HDRBT interview:/pcnrv.blogspot.com/2017/12/questions-to-ask-high-dose-rate.html
And here's an article about
Allen - not an MD
•PSA=7.3, prostate volume=55cc, 8/17 cores G6 5-35% involvement
•SBRT 9 yr onc. results
•SBRT 7 yr QOL results
•treated 10/2010 at age 57 at UCLA,PSA now: 0.1,no lasting urinary, rectal or sexual SEsmy PC blog